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Albumin Roma is an electrophoretically s ow moving genetic variant of human serum albumin found in 22 unrelated 
families. The protein was isolated from the serum of a healthy, heterozygous subject. Analysis of CNBr fragments by 
isoelectric focusing allowed us to localize the mutation to fragment CNBr IV (residues 299-329). This fragment was isola- 
ted on a preparative scale by RP-HPLC and subjected to tryptic digestion. Sequential analysis of twoabnormal tryptic 
peptides, purified by RP-HPLC, revealed that the variant arises from the substitution of glutamic acid 321 by lysine. 
This amino acid replacement, probably resulting from a point mutation in the structural gene, causes a change in the 
net charge of +2 units which is in keeping with the decreased electrophoretic mobility of the native protein. 
Human serum albumin; Genetic variant; Isoelectric focusing; HPLC; Amino acid sequence 
1. INTRODUCTION 
Human serum albumin polymorphism, known 
as bisalbuminemia, is an asymptomatic condition 
expressed with a frequency of about 0.0003 in in- 
dividuals of Caucasian origin [1]. More than one 
hundred genetic variants had been detected during 
routine clinical electrophoresis and classified as 
slow or fast with respect to the electrophoretic 
behaviour of the normal protein [2-4]. The struc- 
tural characterization f the mutants carried out in 
several laboratories has, so far, allowed identifica- 
tion of fourteen different amino acid substitutions 
within the albumin molecule and three in the pro- 
hexapeptide, which account for more than two 
dozen differently named alloalbumins [5-8]. An 
extensive clinical and genetic survey, carried out by 
the Italian Committee for Standardization of 
Hematology and Laboratory Methods (CISMEL), 
has brought up to fourteen electrophoretically dif- 
ferent abnormal albumins of Italian origin to the 
light [9], four of which have been already 
characterized in our laboratory [6]. 
This paper reports the molecular defect of a 
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variant named Roma [2], found in 22 unrelated 
families in Italy, which moves more slowly than 
normal albumin on cellulose acetate elec- 
trophoresis at pH 8.6 [9]. The results reported here 
show that albumin Roma is a new mutant arising 
from the substitution of glutamic acid 321 by 
lysine. 
2. MATERIALS AND METHODS 
2.1. Albumin purification 
A serum sample, obtained from a healthy young man 
heterozygous for the variant, was supplied by Dr F. Porta 
(Ospedale di Circolo, Varese, Italy). Slow and normal albumins 
were separated on a DEAE-Sephadex column eluted with 
0.12 M phosphate buffer, pH 5.75, as described in [6] and 
checked for purity by SDS-gel electrophoresis [10]. 
2.2. Screening of CNBr fragments 
The whole reduced proteins were carboxymethylated as 
described by Swenson et al. [11] and cleaved with olyanogen 
bromide according to Gross [12]. The CNBr digests were com- 
pared by analytical isoelectric focusing performed on 
polyacrylamide gels as previously reported [13]. 
2.3. Peptide purification 
CNBr fragments from albumin Roma were purified on a 
preparative scale by RP-HPLC on a Waters Associated liquid 
chromatograph according to the procedure described by 
ladarola et al. [14]. The abnormal CNBr IV fragment was sub- 
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jected to tryptic cleavage [6] and the digest was resolved by RP- 
HPLC on a/~Bondapak C-18 column (10/~m, 30 cm x 3.9 mm, 
i.d., Waters Assoc.) using the conditions described earlier [l 5]. 
Individual peaks were collected manually and vacuum dried. 
2.4. Structural studies 
Amino acid analyses were carried out by ion-exchange 
chromatography with post-column inhydrin derivatization ac- 
cording to Moore [16] on a Kontron Chromakon 500 automatic 
analyzer. Manual dansyl-Edman degradation was performed 
according to the method of Gray [17]. The amino terminal dan- 
sylated amino acid residue was identified using the procedure of 
Woods and Wang [18] and the solvents described by Hartley 
[191. 
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3. RESULTS AND DISCUSSION 
Normal and Roma albumins were purified by 
ion-exchange chromatography: the abnormal pro- 
tein eluted earlier than the normal one in agree- 
ment with its electrophoretic mobility observed on 
cellulose acetate at pH 8.6. The two homogeneous 
proteins have the same N-terminal residue, Asp, 
and essentially an identical molecular mass, 
66.5 kDa, while comparative amino acid analyses 
do not show any significant differences. The nor- 
mal and variant albumins, after carboxymethyla- 
tion and cleavage with CNBr, were compared by 
analytical gel isoelectric focusing in the pH range 
2.5-8 (fig. 1). The band corresponding to fragment 
CNBr IV of albumin Roma is not present in the 
normal position and appears to comigrate with one 
of the bands corresponding to fragment CNBr III, 
with a change in isoionic point of about 0.4 pH 
units. This finding suggests that the mutation is 
localized in the region between residues 299 and 
329 and consists of a double charge substitution, 
an acidic residue being replaced by a basic one. 
Purification of the modified CNBr IV fragment 
on a preparative, scale was achieved by RP-HPLC: 
comparing the elution profile reported in fig.2 with 
that obtained from normal albumin in the same ex- 
perimental conditions [14], only CNBr IV behaves 
differently, showing a decreased retention time of 
2 min with respect to the corresponding normal 
fragment. N-terminal and amino acid analyses 
were performed on all the purified CNBr 
fragments and, as expected, the amino acid com- 
positions of all peptides, except CNBr IV, were 
identical to the corresponding ones from the nor- 
mal protein. The amino acid analysis of CNBr IV, 
reported in table 1, shows the presence of an addi- 
Fig.1. lsoelectric focusing of CNBr fragments from normal 
(lane 1) and Roma (lane 2) carboxymethylated albumins. 
Peptides were resolved in the pH range 2.5-8 in the presence of
8 M urea. CNBr fragments were originally identified by 
focusing each peptide purified by HPLC under the same 
conditions [14] and are numbered according to their order in the 
known sequence of human serum albumin [201. Fragment 
CNBr II has not been identified, probably owing to i s high 
solubility and low dye affinity. Each fragment, except the C- 
terminal CNBr VII, may have two charge forms, owing to the 
homoserine-homoserine lactone equilibrium. 
Microheterogeneity, mostly in the case of larger fragments, i  
probably due either to partial cleavage or oxidation of 
unreacted cysteines or deamidation. The arrow on the right 
marks the abnormal CNBr IV fragment: i s position has been 
confirmed by focusing the homogeneous fragment inthe same 
conditions. 
tional lysine and the lack of a glutamic acid 
residue, in agreement with the increased isoelectric 
point of the homogeneous modified fragment 
(4.75 for the homoserine C-terminal form, cor- 
responding to a ApI of about + 0.4 pH units). A 
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Fig.2. RP-HPLC elution profile of CNBr fragments from 
carboxymethylated Roma albumin. The digest (120 nmol) was 
dissolved in 0.050/o aqueous trifluoroacetic acid (solvent A) and 
100/~l were injected into a Vydac C-18 column equilibrated with 
8007o solvent A and 2007o aeetonitrile-2-propanol (2: l, v/v) 
containing 0.0507o trifluoroacetic acid (solvent B). The elution 
was performed at room temperature, using a 30 min linear 
gradient from 20070 to 6007o f solvent B. Flow rate, 2 ml/min; 
absorbance range, 1.28 full scale. 
Glu ------, Lys substitution also accounts for the 
HPLC behaviour of the abnormal CNBr IV: in 
fact, this kind of replacement, found in another 
genetic variant of human serum albumin named 
Verona (570 Glu , Lys), decreases the retention 
time of the modified CNBr fragment o the same 
extent [6]. 
The purified CNBr IV fragment from albumin 
Roma was then cleaved with trypsin and the digest 
was resolved by RP-HPLC (fig.3). Each of the six 
peaks obtained was characterized by N-terminal 
and amino acid analyses. The results, reported in 
table 2, account for the whole amino acid content 
of the modified CNBr IV. On the basis of their 
amino acid composition and N-terminal residues 
peptides 2 and 6 fit the normal sequence between 
residues 299 and 317 and peptides 4 and 5 corre- 
spond to the sequence 324-329. Fragments 1 and 
3, which revealed an abnormal amino acid content, 
were submitted to manual dansyl-Edman degrada- 
tion. Fragment 3 shows the sequence Asx-Tyr-Ala- 
Lys corresponding to residues 318-321 except for 
Table I 
Amino acid composition of CNBr 1V fragments from normal 
and Roma albumins 
Amino acid Normal CNBr 1V a Roma CNBr IV b 
Lys 3 4.05 
Cys 1 0.91 c 
Asp 5 5.09 
Ser 2 1.97 
Glu 2 1.08 
Pro 2 2.02 
Gly 1 1.07 
Ala 5 5.03 
Val 3 2.99 
Met 1 0.85 a 
Leu 3 3.04 
Tyr l 0.90 
Phe 2 2.00 
a From sequence in [20] 
b Compositions are given i residues/mol. The values are the 
mean of three independent determinations 
c Determined asS-carboxymethyl-cysteine 
a Present as homoserine 
the substitution of glutamic acid 321 by lysine. 
Fragment 1 is a dipeptide, Ala-Lys, corresponding 
to sequence 322-323, which arises from the tryptic 
cleavage occurring at lysine 321. 
The reported ata state that albumin Roma is a 
new variant arising from a 321 Glu , Lys 
substitution. Although no further sequence 
analysis was undertaken, the finding that only 
CNBr IV behaves differently, when considering 
isoelectric focusing patterns, HPLC retention 
times and amino acid compositions of the CNBr 
fragments, rules out the possibility that additional 
substitutions may occur in other regions of the 
molecule. The Glu -----, Lys mutation of albumin 
Roma corresponds to a single base alteration in the 
structural gene: codon 321, GAG in normal 
albumin [20], is probably changed in AAG en- 
coding for lysine. This change causes a double 
charge substitution which is in keeping with the 
decreased mobility of the native protein at pH 8.6. 
However, the same amino acid replacement 
located in a different region of the molecule causes 
albumin Verona (570 Glu , Lys) to migrate 
more slowly than albumin Roma when compared 
in the same electrophoretic conditions [21]. This 
different electrophoretic behaviour may reflect 
several factors, such as differences in the pKa 
values, degree to which the modified residues are 
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Fig.3. RP-HPLC elution profile of the tryptic digest of CNBr 
IV fragment from albumin Roma. A 200/~l portion (10 nmol) 
of the digest was applied to a /~-Bondapak C-18 column 
equilibrated in 0.05% aqueous trifluoroacetic a id (solvent A). 
Peptides were eluted with a 60 min linear gradient from 
equilibration buffer to 50°/0 acetonitrile containing 0.05% 
trifluoroacetic acid (solvent B). Flow rate, 2 ml/min; 
absorbance range, 0.32 full scale. Peptides were detected by
their absorbance at 220 nm. The numbers above the peaks refer 
to the elution position. Each peak was subjected toamino acid 
and N-terminal analyses (table 2). 
exposed to the solvent and conformat iona l  changes 
due to the substitut ion. Accord ing to the 
theoretical model  of  the a lbumin molecule pro-  
posed by Brown and Shockley [22], glutamic acid 
321 is located five residues away f rom the begin- 
ning of  helix X of  subdomain  2 C, in the outside 
port ion of  the trough- l ike structure of  domain  2, 
while glutamic acid 570 is in the outer surface of  
helix 3 C Z, corresponding to the C-terminal  end 
of  the molecule: this region, which is free from the 
restrictions imposed by the disulf ide bridges, 
probab ly  al lows for more flexibil ity and is less 
shielded from the solvent. Such an exposed posi- 
t ion of  the C-terminal  end o f  the a lbumin molecule 
is in agreement with the fact that also in the fast 
variants character ized so far a charge substitut ion 
in this region has a greater effect on the elec- 
t rophoret ic  mobi l i ty:  a lbumin Mi /Fg  (573 Lys 
Glu) shows a faster anodic mobi l i ty  with respect o 
a lbumin Naskapi  (372 Lys , Glu) and Maku 
(541 Lys , Glu) [5,21], also a lbumin Vanves 
(574 Lys ,Asn)  moves faster than a lbumin 
Tagl iacozzo (313 Lys ,Asn)  [6]. 
As in the case of  other genetic variants,  no 
clinical symptoms eem to be associated with the 
Table 2 
Amino acid composition and N-terminal residues of tryptic fragments of CNBr IV 
from variant Roma a 
Amino acid HPLC peaks (from fig.3) 
1 2 3 4 c 5 c 6 
Lys 1.01 1.02 1.03 1.01 
CM-Cys 0.92 
Asp 1.02 1.03 1.03 1.01 2.02 
Ser 1.97 
Glu 1.03 
Pro 2.00 
Gly 1.06 1.04 
Ala 0.99 1.01 2.97 
Val 1.04 1.03 1.04 0.99 
Leu 1.03 1.03 2.03 
Tyr 0.93 
Phe 1.00 1.01 0.98 
Homoserine 0.85 0.87 
N-terminal Ala Asx Asx Asx Asx Pro 
Position in the 
sequence b 322-323 314-317 318-321 324-329 324-329 299-313 
a The values are determined based on a calculated average nmol/residue 
b According to Minghetti [20] 
c The presence of two peptides with the same amino acid composition is due to the 
homoserine-homoserine lactone quilibrium 
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presence of albumin Roma in all the observed sub- 
jects. Although subdomain 2 C is thought o be the 
primary steroid-binding site and also a binding site 
for long chain fatty acids, glutamic acid 321 is not 
directly involved in these bindings [22]; thus, it 
seems likely that the 321 Glu , Lys substitution, 
which is conservative with respect to the 
hydrophilicity parameters [23], does not affect the 
transport functions of albumin Roma. 
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